Lost in disruption: Role of proteases in glioma invasion and progression

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 2, 2012, Pages 178-185

  Mentlein, Rolf ^a   Hattermann, Kirsten ^a   Held Feindt, Janka ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Astrocytoma; Chemokines; Extracellular matrix; Growth factors; Invasion; Protease

Indexed keywords

ADAM PROTEIN; ADAMTS PROTEIN; AGGRECAN; BREVICAN; CATHEPSIN B; CELL ADHESION MOLECULE; CHEMOTACTIC FACTOR; GROWTH FACTOR; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUROCAN; PROTEINASE; PROTEOGLYCAN; SERINE PROTEINASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VERSICAN;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; AUTOCRINE EFFECT; BRAIN TISSUE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CARCINOGENESIS; CELL HETEROGENEITY; CELL INTERACTION; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME RELEASE; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; MUSCULOSKELETAL DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT;

ANIMALS; BRAIN NEOPLASMS; DISEASE PROGRESSION; GLIOMA; HUMANS; NEOPLASM INVASIVENESS; PEPTIDE HYDROLASES;

EID: 84856070578     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.12.001     Document Type: Review

References (95)

1. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
2. Nieder C., Adam M., Grosu A.L. Combined modality treatment of glioblastoma multiforme: the role of temozolomide. Rev. Recent Clin. Trials 2006, 1:43-51.
3. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
4. Claes A., Idema A.J., Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol. 2007, 114:443-458.
5. Silbergeld D.L., Chicoine M.R. Isolation and characterization of human malignant glioma cells from histologically normal brain. J. Neurosurg. 1997, 86:525-531.
6. Salcman M. Glioblastoma and malignant astrocytomas. Brain Tumours: An Encyclopaedic Approach 1995, 449-477. A.H. Kaye and E.R. Laws, Churchill Livingstone, New York, NY.
7. Scherer H.J. Structural development in gliomas. Am. J. Cancer 1938, 34:331-351.
8. Holland E.C. Glioblastoma multiforme: the terminator. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6242-6244.
9. Louis D.N. Molecular pathology of malignant gliomas. Annu. Rev. Pathol. 2006, 1:97-117.
10. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
11. Binder D.K., Berger M.S. Proteases and the biology of glioma invasion. J. Neurooncol. 2002, 56:149-158.
12. Levicar N., Nuttall R.K., Lah T.T. Proteases in brain tumour progression. Acta Neurochir. (Wien) 2003, 145:825-838.
13. Nakada M., Okada Y., Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front. Biosci. 2003, 8:e261-e269.
14. Rao J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 2003, 3:489-501.
15. Rivera S., Khrestchatisky M., Kaczmarek L., Rosenberg G.A., Jaworski D.M. Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?. J. Neurosci. 2010, 30:15337-15357.
16. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol. Aspects Med. 2008, 29:258-289.
17. Turner S.L., Blair-Zajdel M.E., Bunning R.A. ADAMs and ADAMTSs in cancer. Br. J. Biomed. Sci. 2009, 66:117-128.
18. Pruessmeyer J., Ludwig A. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin. Cell Dev. Biol. 2009, 20:164-174.
19. Saftig P., Reiss K. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: Novel drug targets with therapeutic potential?. Eur. J. Cell Biol. 2011, 90:527-535.
20. Mori T., Abe T., Wakabayashi Y., Hikawa T., Matsuo K., Yamada Y., Kuwano M., Hori S. Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. J. Neurooncol. 2000, 46:115-123.
21. Oh J.W., Olman M., Benveniste E.N. CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells. Biol. Pharm. Bull. 2009, 32:573-577.
22. Piek E., Westermark U., Kastemar M., Heldin C.H., van Zoelen E.J., Nister M., Ten Dijke P. Expression of transforming-growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-beta1. Int. J. Cancer 1999, 80:756-763.
23. Reiser J., Adair B., Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J. Clin. Invest. 2010, 120:3421-3431.
24. Rauch U. Brain matrix: structure, turnover and necessity. Biochem. Soc. Trans. 2007, 35:656-660.
25. Alves T.R., da Fonseca A.C., Nunes S.S., da Silva A.O., Dubois L.G., Faria J., Kahn S.A., Viana N.B., Marcondes J., Legrand C., Moura-Neto V., Morandi V. Tenascin-C in the extracellular matrix promotes the selection of highly proliferative and tubulogenesis-defective endothelial cells. Exp. Cell Res. 2011, 317:2073-2085.
26. Zimmermann D.R., Dours-Zimmermann M.T. Extracellular matrix of the central nervous system: from neglect to challenge. Histochem. Cell Biol. 2008, 130:635-653.
27. Ruoslahti E. Brain extracellular matrix. Glycobiology 1996, 6:489-492.
28. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell. Mol. Life Sci. 2000, 57:276-289.
29. Viapiano M.S., Bi W.L., Piepmeier J., Hockfield S., Matthews R.T. Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res. 2005, 65:6726-6733.
30. Zhang H., Kelly G., Zerillo C., Jaworski D.M., Hockfield S. Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion in vivo. J. Neurosci. 1998, 18:2370-2376.
31. Bourdon M.A., Wikstrand C.J., Furthmayr H., Matthews T.J., Bigner D.D. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983, 43:2796-2805.
32. Maris C., Rorive S., Sandras F., D'Haene N., Sadeghi N., Bièche I., Vidaud M., Decaestecker C., Salmon I. Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas. Neuropathol. Appl. Neurobiol. 2008, 34:316-329.
33. Huang J.Y., Cheng Y.J., Lin Y.P., Lin H.C., Su C.C., Juliano R., Yang B.C. Extracellular matrix of glioblastoma inhibits polarization and transmigration of T cells: the role of tenascin-C in in immune suppression. J. Immunol. 2010, 185:1450-1459.
34. Martina E., Degen M., Rüegg C., Merlo A., Lino M.M., Chiquet-Ehrismann R., Brellier F. Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro. FASEB J. 2010, 24:778-787.
35. Sarkar S., Nuttall R.K., Liu S., Edwards D.R., Yong V.W. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res. 2006, 66:11771-11780.
36. Pilkington G.J. The paradox of neoplastic glial cell invasion of the brain and apparent metastatic failure. Anticancer. Res. 1997, 17:4103-4105.
37. Subramanian A., Harris A., Piggott K., Shieff C., Bradford R. Metastasis to and from the central nervous system-the 'relatively protected site'. Lancet Oncol. 2002, 3:498-507.
38. Ng W.H., Yeo T.T., Kaye A.H. Spinal and extracranial metastatic dissemination of malignant glioma. J. Clin. Neurosci. 2005, 12:379-382.
39. Nakada M., Miyamori H., Kita D., Takahashi T., Yamashita J., Sato H., Miura R., Yamaguchi Y., Okada Y. Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol. 2005, 110:239-246.
40. Nakamura H., Fujii Y., Inoki I., Sugimoto K., Tanzawa K., Matsuki H., Miura R., Yamaguchi Y., Okada Y. Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites. J. Biol. Chem. 2000, 275:38885-38890.
41. Held-Feindt J., Paredes E.B., Blomer U., Seidenbecher C., Stark A.M., Mehdorn H.M., Mentlein R. Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int. J. Cancer 2006, 118:55-61.
42. Matthews R.T., Gary S.C., Zerillo C., Pratta M., Solomon K., Arner E.C., Hockfield S. Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J. Biol. Chem. 2000, 275:22695-22703.
43. Lettau I., Hattermann K., Held-Feindt J., Brauer R., Sedlacek R., Mentlein R. Matrix metalloproteinase-19 is highly expressed in astroglial tumors and promotes invasion of glioma cells. J. Neuropathol. Exp. Neurol. 2010, 69:215-223.
44. Nuttall R.K., Pennington C.J., Taplin J., Wheal A., Yong V.W., Forsyth P.A., Edwards D.R. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol. Cancer Res. 2003, 1:333-345.
45. Hu B., Kong L.L., Matthews R.T., Viapiano M.S. The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J. Biol. Chem. 2008, 283:24848-24859.
46. Wick W., Platten M., Weller M. Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J. Neurooncol. 2001, 53:177-185.
47. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85:683-693.
48. Deryugina E.I., Bourdon M.A., Luo G.X., Reisfeld R.A., Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J. Cell Sci. 1997, 110:2473-2482.
49. Fillmore H.L., VanMeter T.E., Broaddus W.C. Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J. Neurooncol. 2001, 53:187-202.
50. Aaberg-Jessen C., Christensen K., Offenberg H., Bartels A., Dreehsen T., Hansen S., Schroder H.D., Brunner N., Kristensen B.W. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J. Neurooncol. 2009, 95:117-128.
51. Groft L.L., Muzik H., Rewcastle N.B., Johnston R.N., Knauper V., Lafleur M.A., Forsyth P.A., Edwards D.R. Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas. Br. J. Cancer 2001, 85:55-63.
52. Nakano A., Tani E., Miyazaki K., Yamamoto Y., Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J. Neurosurg. 1995, 83:298-307.
53. Silveira Correa T.C., Massaro R.R., Brohem C.A., Taboga S.R., Lamers M.L., Santos M.F., Maria-Engler S.S. RECK-mediated inhibition of glioma migration and invasion. J. Cell. Biochem. 2010, 110:52-61.
54. Lamfers M.L., Gianni D., Tung C.H., Idema S., Schagen F.H., Carette J.E., Quax P.H., Van Beusechem V.W., Vandertop W.P., Dirven C.M., Chiocca E.A., Gerritsen W.R. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res. 2005, 65:9398-9405.
55. Lu K.V., Jong K.A., Rajasekaran A.K., Cloughesy T.F., Mischel P.S. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab. Invest. 2004, 84:8-20.
56. Hoelzinger D.B., Demuth T., Berens M.E. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J. Natl. Cancer Inst. 2007, 99:1583-1593.
57. Mueller M.M., Werbowetski T., Del Maestro R.F. Soluble factors involved in glioma invasion. Acta Neurochir. (Wien) 2003, 145:999-1008.
58. Hart S., Fischer O.M., Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 2004, 64:1943-1950.
59. Lorente M., Carracedo A., Torres S., Natali F., Egia A., Hernandez-Tiedra S., Salazar M., Blazquez C., Guzman M., Velasco G. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. Glia 2009, 57:1374-1385.
60. Held-Feindt J., Hattermann K., Muerkoster S.S., Wedderkopp H., Knerlich-Lukoschus F., Ungefroren H., Mehdorn H.M., Mentlein R. CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Exp. Cell Res. 2010, 316:1553-1566.
61. Ludwig A., Schulte A., Schnack C., Hundhausen C., Reiss K., Brodway N., Held-Feindt J., Mentlein R. Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J. Neurochem. 2005, 93:1293-1303.
62. Leitlein J., Aulwurm S., Waltereit R., Naumann U., Wagenknecht B., Garten W., Weller M., Platten M. Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J. Immunol. 2001, 166:7238-7243.
63. Kodama T., Ikeda E., Okada A., Ohtsuka T., Shimoda M., Shiomi T., Yoshida K., Nakada M., Ohuchi E., Okada Y. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am. J. Pathol. 2004, 165:1743-1753.
64. Mentlein R., Forstreuter F., Mehdorn H.M., Held-Feindt J. Functional significance of vascular endothelial growth factor receptor expression on human glioma cells. J. Neurooncol. 2004, 67:9-18.
65. Mentlein R., Held-Feindt J. Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J. Neurochem. 2002, 83:747-753.
66. Abounader R., Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 2005, 7:436-451.
67. Mentlein R., Hattermann K., Hemion C., Jungbluth A.A., Held-Feindt J. Expression and role of the cell surface protease seprase/fibroblast activation protein-alpha (FAP-alpha) in astroglial tumors. Biol. Chem. 2011, 392:199-207.
68. Stremenova J., Krepela E., Mares V., Trim J., Dbaly V., Marek J., Vanickova Z., Lisa V., Yea C., Sedo A. Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. Int. J. Oncol. 2007, 31:785-792.
69. Balaziova E., Busek P., Stremenova J., Sromova L., Krepela E., Lizcova L., Sedo A. Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-α in transformed astrocytic cells. Mol. Cell. Biochem. 2011, 354:283-289.
70. Keane F.M., Nadvi N.A., Yao T.W., Gorrell M.D. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J. 2011, 278:1316-1332.
71. Eisele G., Wischhusen J., Mittelbronn M., Meyermann R., Waldhauer I., Steinle A., Weller M., Friese M.A. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006, 129:2416-2425.
72. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
73. Jansen M., Yip S., Louis D.N. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010, 9:717-726.
74. Inoue A., Takahashi H., Harada H., Kohno S., Ohue S., Kobayashi K., Yano H., Tanaka J., Ohnishi T. Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity. Int. J. Oncol. 2010, 37:1121-1131.
75. Annabi B., Laflamme C., Sina A., Lachambre M.P., Beliveau R. A MT1-MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in CD133+ U87 glioblastoma cells. J. Neuroinflammation 2009, 6:8.
76. Charles N.A., Holland E.C., Gilbertson R., Glass R., Kettenmann H. The brain tumor microenvironment. Glia 2011, 9:1169-1180.
77. Badie B., Schartner J. Role of microglia in glioma biology. Microsc. Res. Tech. 2001, 54:106-113.
78. Hwang S.Y., Yoo B.C., Jung J.W., Oh E.S., Hwang J.S., Shin J.A., Kim S.Y., Cha S.H., Han I.O. Induction of glioma apoptosis by microglia-secreted molecules: The role of nitric oxide and cathepsin B. Biochim. Biophys. Acta 2009, 1793:1656-1668.
79. Lin H.C., Song T.Y., Hu M.L. S-Adenosylhomocysteine promotes the invasion of C6 glioma cells via increased secretion of matrix metalloproteinase-2 in murine microglial BV2 cells. Toxicol. Sci. 2009, 112:322-330.
80. Wang J., Tsirka S.E. Contribution of extracellular proteolysis and microglia to intracerebral hemorrhage. Neurocrit. Care 2005, 3:77-85.
81. Markovic D.S., Vinnakota K., Chirasani S., Synowitz M., Raguet H., Stock K., Sliwa M., Lehmann S., Kalin R., van Rooijen N., Holmbeck K., Heppner F.L., Kiwit J., Matyash V., Lehnardt S., Kaminska B., Glass R., Kettenmann H. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12530-12535.
82. Onishi M., Ichikawa T., Kurozumi K., Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol. 2011, 28:13-24.
83. Hattermann K., Held-Feindt J., Lucius R., Sebens-Müerköster S., Penfold M.E., Schall T.J., Mentlein R. The chemokine receptor CXCR7is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res. 2010, 70:3299-3308.
84. Kenig S., Alonso M.B., Mueller M.M., Lah T.T. Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. Cancer Lett. 2010, 289:53-61.
85. Mentlein R. Cell-surface peptidases. Int. Rev. Cytol. 2004, 235:165-213.
86. VanMeter T.E., Rooprai H.K., Kibble M.M., Fillmore H.L., Broaddus W.C., Pilkington G.J. The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. J. Neurooncol. 2001, 53:213-235.
87. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
88. Pavlaki M., Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 2003, 22:177-203.
89. Drummond A.H., Beckett P., Brown P.D., Bone E.A., Davidson A.H., Galloway W.A., Gearing A.J., Huxley P., Laber D., McCourt M., Whittaker M., Wood L.M., Wright A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. N. Y. Acad. Sci. 1999, 878:228-235.
90. Strongin A.Y. Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim. Biophys. Acta 2010, 1803:133-141.
91. Binder B.R., Mihaly J. The plasminogen activator inhibitor "paradox" in cancer. Immunol. Lett. 2008, 118:116-124.
92. Groves M.D., Puduvalli V.K., Hess K.R., Jaeckle K.A., Peterson P., Yung W.K., Levin V.A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 2002, 20:1383-1388.
93. Gabelloni P., Da Pozzo E., Bendinelli S., Costa B., Nuti E., Casalini F., Orlandini E., Da Settimo F., Rossello A., Martini C. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Neuroscience 2010, 168:514-522.
94. Tremont-Lukats I.W., Gilbert M.R. Advances in molecular therapies in patients with brain tumors. Cancer Control 2003, 10:125-137.
95. Lah T.T., Durán Alonso M.B., Van Noorden C.J. Antiprotease therapy in cancer: hot or not?. Expert. Opin. Biol. Ther. 2006, 6:257-279.